Phase 1 Strategic Synthesis · Near & Dear · 2026

Year One showed us where the opening is.

The signals are clear, the lane is unclaimed, and the window is open. Here’s what the data taught us — and how we move.

What we learned

The content that earned the most wasn’t the content we posted most. UGC & practice content earned a 3.10% ER on 12% of volume. INNM campaign content hit 4.65% — the account’s top-performing pillar. Meanwhile, document posts on LinkedIn averaged 34.5% engagement rate, with 91% of engagements being active post clicks. Two platforms, two completely different jobs — and the data is telling us exactly how to use them.

The open lane

Cold Clinical, Celebrity Halo, Wellness Glow — all taken. Comfort + Science + Warmth sits unclaimed. Jeisys is already built for it.

How we move

Structural, not tactical. Rebalance toward what’s already working, claim the positioning lane the market left open, and build the post-purchase infrastructure that turns providers into advocates.

The Landscape

The category mapped itself into a corner.

Every major competitor staked a position — clinical authority, celebrity heat, wellness glow. None of them saw what they left open. Every provider pain point and patient frustration in this chapter points at the same gap.

0
Competitors own
Comfort + Science + Warmth

The intersection of medical-grade outcomes and genuine warmth sits completely unclaimed — in a $5.5B market already moving toward exactly that.

Competitive Territory Map
← Clinical / Cold                  Warm / Human →
Taken

Cold Clinical

Thermage, Secret RF, Evoke. Navy / silver / chrome. Device-as-hero. Reads as medical infrastructure, not a woman's choice.

Thermage FLX Secret RF Evoke Cutera
Taken

Celebrity Halo

Morpheus8, MOXI, Sofwave. Kardashian + Bieber + Aniston. Powered by celebrity heat — but patient sentiment is turning cautionary.

Morpheus8 MOXI Sofwave
Taken

Wellness Glow

HydraFacial, Clear+Brilliant. Owns the sensory floor. Strong on comfort, light on clinical credibility. Doesn't compete on outcomes.

HydraFacial Clear+Brilliant
Open

Comfort + Science + Warmth

Medical-grade outcomes delivered with the warmth of a partner brand. Comfort as a real claim. Science as the foundation, not the whole pitch. The audience is already there — no competitor has staked it.

Jeisys Territory

MOXI is extending down. HydraFacial is extending up. The lane is open now.

Provider Pain Points

What device companies aren't delivering — and what that gap costs practices every day. The complaints are consistent across every practice type. Only the shape of the pain changes.

Abandoned after the sale

The single most consistent complaint in HCP research. Reps push hard to close, then go dark. No community, no assets, no one to call. The device arrives. The support doesn't.

Toolkits that look like marketing but don't work like it

Generic brochures and stock images that no patient ever acted on. Solo practices need copy-paste-ready social posts and patient-facing content their existing audience will actually engage with.

A painful device is a reputation problem — and it's not their fault

Pain complaints, grid-mark scarring, fat-loss documentation — all over TikTok and Reddit. The device brand survives the blowback. The solo practice absorbs it.

Training takes days. Most practices don't have days.

Training-heavy onboarding pulls clinical staff offline and pushes the ROI timeline out by months. Device companies price it in. Solo practices pay for it in lost revenue.

They have to sell this upward. Nobody's built the tools for that.

Practice leads sell internally before any device brand shows up. Solo-practice case studies don't survive that conversation. They need chain-level proof: multi-location utilization data, standardized rollout playbooks. Almost no one has built this.

Chains scale by training one person. Most brands still train them one by one.

A chain with 8 locations can't pull staff offline 8 times. Train-the-trainer is the only model that scales. Most device companies still don't offer it — which means the economics of onboarding break before the device earns a dollar.

The ROI math exists. Nobody's built it for chains.

Section 179 and solo-practice ROI tools don't translate. Chain buyers need cross-location utilization math, marketing co-op ROI, and consolidated billing economics. That document doesn't exist yet — so the close relies on intuition instead of evidence.

They expect a strategic partner. Most device brands show up to close.

Chain buyers expect QBRs, account-level rep relationships, and input on portfolio strategy. Device companies show up to sell. The gap between “vendor” and “partner” is exactly where Jeisys can plant a flag.

Case in pointInMode declared 2026 “not a growth year — a stabilization year” on their Q4 2025 earnings call (Feb 10, 2026). Chain accounts report rep turnover and delayed responses mid-cycle. (InMode Q4 2025 Earnings Call, Motley Fool transcript)

The patients are talking. The scores are dropping.

Morpheus8 was the gold standard. It's now the cautionary tale. Current RealSelf Worth It score: 66% — driven by documented pain complaints, grid-mark scarring, and fat-loss side effects across hundreds of patient reviews. Practices riding it out are absorbing blowback that isn't theirs. (RealSelf.com, retrieved May 2026)

Target

Morpheus8 (InMode) practices

Cutera went bankrupt. Now what?

Based on available reporting: Chapter 11 in March 2025, Nasdaq delisting, emerged private May 2025. Cutera continues to operate under private ownership, but provider forums reflect real uncertainty around long-term consumables, tip supply, and software support. Practices invested in Secret RF are asking questions their rep can't fully answer yet.

TargetCutera Secret RF, Excel V+, Enlighten practices

A 20-year-old brand. A 2018 device. No comfort innovation since.

Thermage is a legacy brand — the FLX is its current-generation device, launched in 2018. Operators still call it physically uncomfortable. Patients still call it painful. The pedigree is real. The momentum isn't. DENSITY beats it on every axis — collagen output, comfort, and consistency.

TargetThermage FLX (Solta) practices

The results depend entirely on who's holding the device.

Ultrasound-class devices punish learning curves. Sofwave and Ultherapy results vary heavily by operator — and practices new to the category pay for that inconsistency in patient trust before they ever build proficiency.

TargetSofwave, Ultherapy practices

Providers aren't the only ones paying for this gap.

Patient Pain Points

She already knows what she wants. The category still hasn’t figured out how to give it to her. (MRI Aesthetics, Jul 2025 · 73% women · median age 37 · HHI $145K)

01
She doesn’t want to fix aging. She wants to glow.
The deficit frame — “ease lines,” “fight aging” — reads like fear, not aspiration. She wants to look like herself on her best day. Most medical-grade brands still haven’t made that pivot.
Jeisys Answer
Lead with glow, not deficit. DENSITY’s collagen-banking positioning and the K-beauty heritage are already there — the creative just needs to use them.
02
She wants to share it like she shares her facialist.
Clinical framing turns treatments into something you whisper about. She wants aesthetics to feel like her Pilates studio or supplement routine — something she can post about, recommend, be proud of.
Jeisys Answer
The “Business BFF of aesthetics” voice is built for this. UGC-ready content kits, provider IG amplification, and the Glow Getter loyalty arc turn treatment into something she broadcasts.
03
She’s done the research. Nobody’s told her what the room looks like.
She knows the mechanism. She knows the claims. What she doesn’t know is what walking in feels like or what her face looks like Thursday. Most brand sites jump straight to “book a consultation.”
Jeisys Answer
Day-of content, honest recovery timelines by protocol tier, and treatment experience storytelling. EdgePolish™’s 10-minute narrative was built for exactly this conversion gap.
04
RF, ultrasound, CO² — she can’t tell them apart.
The category education that exists was written by brands trying to win, not help her decide. She searches for an honest comparison and finds competing claims.
Jeisys Answer
Build the neutral category guide she’s searching for. An honest RF vs. ultrasound vs. CO² comparison — plain language, recovery mapped by tier. The brand that publishes it first owns her trust.
05
She expects a wellness-club experience. She’s getting a waiting room.
Soft lighting, considered scent, hospitality-grade hosting — she expects the register of her fitness studio. Most device brands’ patient-facing content still photographs like a clinic.
Jeisys Answer
DENSITY’s Smart Adjustable Cooling. No needles, no downtime. K-beauty heritage. The creative direction already exists — it just needs to show the room, not the device.

Category Whitespace

Three conversations the audience is already having. None of them have an owner yet.

Collagen Banking

Gift-wrapped for DENSITY

Patients in their 20s and 30s are searching "preventative aesthetics" and "banking collagen" right now. No medical-grade device brand owns the term. DENSITY's mechanism IS collagen banking — the brand strategy already names the Collagen Banker sub-segment.

Ozempic / GLP-1 Face

First-mover open

GLP-1 use is exploding. Practices are watching facial volume disappear weekly. Filler brands own volume-restoration. No collagen-stimulation brand has stepped up. DENSITY's collagen-stimulation positioning plus the GLP-1 sub-segment = a head start no competitor has.

Aesthetics as Wellness

Full brand frame

She thinks of aesthetics the same way she thinks of Pilates, supplements, and HRT — as a practice, not a procedure. Medical-grade brands still talk in treatments. HydraFacial owns the sensory floor. Nobody has claimed medical-grade-meets-wellness-stack.

True Skin-of-Color Safety

Defensible lane

PIH risk in Fitzpatrick IV+ skin is documented across most aesthetic devices. Providers are fielding it. Most brands bury it or avoid it. DENSITY's dual-mode RF and Smart Adjustable Cooling were engineered for this patient. Pair with the KOL diversity already mapped in personas.

The category has gaps.

One of them is Jeisys‑shaped.

No competitor owns the intersection of medical-grade outcomes, genuine warmth, and provider partnership. The window is open. What follows is who’s leaving it empty.

Competitive Audit

Three strategic openings across Potenza, DENSITY, and Edge ONE. Nine competitors across three lanes. The verbal whitespace is wider than any of them know.

Positioning Map — Comfort vs. Results

Every major competitor plotted on two axes. Jeisys devices land in the unclaimed top-right quadrant — high results, high comfort — that no one else occupies. Positioning reflects Near & Dear's assessment based on Phase 1 research; not a clinical claim.

↑ Hover any dot for competitor context

Comfort + Science + Warmth Comfort → Results → Low High Low High Fraxel Morpheus8 Thermage FLX Secret RF Genius RF Sofwave Vivace MOXI Emface HydraFacial Clear+Brilliant Ultherapy Potenza DENSITY Edge ONE
Competitor
DENSITY
Potenza
Edge ONE
Shaded region = unclaimed Jeisys territory
Verbal Whitespace

Every competitor owns one word.
Two territories are still unclaimed.

Already Owned
TightenThermage
LiftSofwave
RemodelMorpheus8 / Evoke
ExperienceVivace
PrejuvenationMOXI
GlowHydraFacial
CoolPeelCartessa / DEKA
SecretCutera
Vacant · DENSITY
Consistency

Every Reddit and RealSelf complaint secretly asks for it: "will this actually work the same way on me?" No one has owned it. DENSITY's Real-Time Auto Calibration is the only device built to deliver it.

Vacant · EdgePolish™
Resurfacing in 10

MOXI owns "prejuvenation" but can't say "resurfacing." HydraFacial owns "glow" but can't say "CO₂." CoolPeel owns "CO₂" but trades depth for a peel. The only device that can pair "real fractional CO₂" + "10 minutes" + "zero downtime" — and no competitor can follow.

Competitor Landscape by Device Lane

Potenza by Jeisys
Potenza · Jeisys
Potenza
Jeisys Medical · RF Microneedling

The original — returned to its original maker. Earned confidence, not borrowed credibility.

Where Potenza wins
  • 91% RealSelf "Worth It" — category-leading
  • 4 RF modes vs. Vivace's 1 and Morpheus8's 1
  • Ultra-fine needles + adjustable depth — comfort engineered in
  • Singular focus — not buried inside a parent portfolio
Morpheus8 by InMode
Competitor
Morpheus8
InMode

RFMN gold standard turning cautionary. InMode publicly called 2026 a "stabilization year."

Where they win
  • Largest installed base in RF microneedling
  • Category-defining brand recognition
Where they lose
  • RealSelf "Worth It" 97% → 65% over the trailing several years*
  • Pain, grid-mark scarring, fat-loss documented on TikTok / Reddit
  • Single-mode RF — no comfort, depth, or versatility narrative
Genius RF by Cynosure Lutronic
Competitor
Genius RF
Cynosure Lutronic

Feature-led not benefit-led ("500×/sec impedance"). Story doesn't reach patients.

Where they win
  • Real clinical credibility on the spec sheet
Where they lose
  • Brand diluted inside Cynosure portfolio alongside XERF
  • No singular voice; spec-led messaging skips the patient
Vivace RF by Cartessa
Competitor
Vivace RF
Cartessa

"The Vivace Experience" — experience-led positioning with a 67% RealSelf score, where negative reviews center on pain and grid marks.

Where they win
  • Experience-led brand language patients respond to
Where they lose
  • Cartessa's 2025 spotlight shifted to EVERESSE
  • "Too subtle for the price" is the dominant patient note
  • Single-mode RF without depth or comfort proof
Secret RF / PRO by Cutera
Competitor
Secret RF / PRO
Cutera — post-Ch. 11

Largest legacy RFMN social footprint — but signal has gone quiet since restructuring.

Where they win
  • ~54K followers @secretbycutera — biggest installed loyalty
Where they lose
  • Chapter 11 March 2025; emerged private May 2025
  • No confirmed 2025–26 hardware launches
  • Provider anxiety about consumables and service continuity is acute
Potenza's verbal whitespace

"Comfort + depth + versatility." No competitor pairs 4-mode RF with actual comfort data and a 91% RealSelf Worth It score. Morpheus8 has depth but not comfort. Vivace has comfort but not depth. "The original." Potenza is the device that returned to its original maker — earned confidence, not borrowed credibility.

DENSITY by Jeisys
DENSITY · Jeisys
DENSITY
Jeisys Medical · Non-invasive RF

No needles, no downtime. Engineered for the consistency every other RF promises.

Where DENSITY wins
  • Dual-mode RF (sequential monopolar + bipolar) — no one else pairs both
  • Real-Time Auto Calibration eliminates operator variance
  • Smart Adjustable Cooling — comfort baked into the engineering, not the marketing
  • Up to 5× more collagen vs. monopolar RF alone, no downtime
Thermage FLX by Solta (Bausch Health)
Competitor
Thermage FLX
Solta (Bausch Health)

Pedigree without momentum. 24+ year-old brand, 2018 FLX device, $2,500–4,000 per session.

Where they win
  • Category legacy — owns the word "tighten"
  • Premium price anchor protects their market
Where they lose
  • Patient sentiment cites pain and heat
  • Monopolar-only, operator-dependent
  • No forward momentum — no platform investment
Ultherapy Prime by Merz Aesthetics
Competitor
Ultherapy Prime
Merz Aesthetics

Declining incumbent — Merz is prioritizing injectables, not the device.

Where they win
  • Broad install base, ultrasound visualization
Where they lose
  • Widely reported pain
  • 12+ month treatment intervals
  • Patient sentiment and Merz's investment direction have moved on
XERF by Cynosure Lutronic
Competitor
XERF
Cynosure Lutronic

K-beauty RF narrative, FDA-cleared Aug 2025. Feature story without real differentiation.

Where they win
  • Recent FDA clearance + K-beauty halo
  • 2-session protocol simplicity at $1,800/treatment
Where they lose
  • Monopolar bulk-heat only — no scar/texture/depth claim
  • Brand diluted inside Cynosure portfolio alongside Genius RF
Sofwave SUPERB
Competitor
Sofwave SUPERB
Sofwave Medical

Celebrity-powered ultrasound — but the results narrative is turning cautionary.

Where they win
  • Kim and Khloé co-sign heat
  • Synchronous parallel beam tech, $1,500–3,000/session
Where they lose
  • RealSelf: "painful, no results, thinner face regret"
  • Ultrasound-only — no RF mechanism, no scar or texture claim
DENSITY's verbal whitespace

"Consistency." Every Reddit and RealSelf complaint secretly asks: "will this work the same way on me?" Thermage owns "tighten." Sofwave owns "lift." Evoke owns "remodel." No one has claimed the word every patient actually wants. DENSITY's Real-Time Auto Calibration + dual-mode RF is the only device in the lane built to deliver it. Lead: "more collagen, more comfort, more consistency."

Edge ONE by Jeisys
Edge ONE · Jeisys
Edge ONE
Jeisys Medical · Fractional CO₂

Resurfacing in 10. The only fractional CO₂ that pairs real ablation depth with a 10-minute protocol.

Where Edge ONE wins
  • Real CO₂ ablation depth — non-ablative competitors structurally cannot match
  • EdgePolish™: 10-minute CO₂ with zero downtime
  • Three-tier ladder: EdgePolish™ → Rejuvenation → Deep Renewal upsell path
  • Pairs with HydraFacial — doesn't compete with cleanse-and-glow
MOXI by Sciton
Competitor
MOXI
Sciton

Coined "prejuvenation." Celebrity halo carrying it — but ceiling is real.

Where they win
  • Hailey Bieber, Sydney Sweeney, Aniston co-signs
  • Owns "prejuvenation" as patient-facing language
Where they lose
  • Non-ablative ceiling — cannot claim "real CO₂ resurfacing"
  • Requires 3–4 sessions; "MOXI ruined my skin" (melasma flare) documented on RealSelf
  • Sciton's HALO TRIBRID now packages MOXI's wavelength capability into a multi-treatment platform — diluting MOXI's standalone story
Fraxel DUAL / FTX by Solta Medical
Competitor
Fraxel DUAL / FTX
Solta Medical

FTX refresh April 2025. Non-ablative by design — structurally bounded.

Where they win
  • Solta legacy + broad existing install base
Where they lose
  • RealSelf Worth It fallen to 65%*
  • PIH in Fitzpatrick IV+ documented
  • Non-ablative ceiling cannot reach Edge ONE's CO₂ depth
Tetra CoolPeel by Cartessa / DEKA
Competitor
Tetra CoolPeel
Cartessa / DEKA

NewBeauty "Best CO₂" five consecutive years. Fastest-growing direct head-to-head threat.

Where they win
  • Owns the word "CoolPeel"
  • 92% RealSelf "Worth It"
  • "10-minute CO₂" framing competes directly with EdgePolish™
Where they lose
  • Single treatment depth — no glow-tier upsell path
  • No structural answer to a three-tier ladder (EdgePolish™ → Rejuvenation → Deep Renewal)
Edge ONE's verbal whitespace

"Resurfacing in 10." EdgePolish™ is the only device that can legally pair "real fractional CO₂" + "10 minutes" + "zero downtime" in the same sentence. MOXI owns "prejuvenation" but can't say "resurfacing." HydraFacial owns "glow" but can't say "CO₂." CoolPeel owns "CO₂" but trades depth for a peel. Don't attack HydraFacial — reframe the practice menu: "Keep HydraFacial for cleanse-and-glow; add EdgePolish™ for the results patients actually came for."

Patient Complaints · Jeisys Answers

The four complaints driving patients to research alternatives — and the answer Jeisys already has for each one.

Three Strategic Openings

Three competitors. Three windows. Move now or watch someone else claim the ground.

Potenza
Morpheus8 Conquest + Secret RF Migration
InMode declared 2026 a stabilization year. Cutera is post-Ch. 11. Build trade-in offers for stranded Secret RF accounts + a comparative safety narrative against Morpheus8.
KPI 30 migration conversations + 8 closed-wons by Q3
DENSITY
Launch “The Density Difference”
Claim “more collagen, more comfort, more consistency” against Thermage, Sofwave/Ultherapy, XERF, and Evoke/Forma. Lead with KOL-authored content + paid search against competitor branded terms.
KPI DENSITY SOV vs. Thermage, XERF, Sofwave
EdgePolish™
Land the Glow-Tier Claim
Claim “real fractional CO² resurfacing in 10 minutes” — no glow-tier competitor can legally say this. Position vs. HydraFacial, MOXI/Clear+Brilliant, and DiamondGlow practices. Day-one: booth, website, rep talk tracks, KOL content.
KPI EdgePolish™ SOV vs. Tetra CoolPeel + MOXI · paid-media CTR benchmark set

Nine competitors. Three lanes. None of them own what Jeisys is built to claim.

Personas

Four providers. One patient. Every one of them is already in the market — and every one of them is looking for a reason to trust someone. Jeisys has one.

Provider Personas

Click any persona to expand the full profile.

Source: Jeisys 2026 Provider & Patient Personas — Near & Dear × Okay Human commissioned research, n=30 qualitative HCP interviews, Dec 2025.

01
The Owner-Operator NP
NP-owned medspa · DENSITY entry point · highest conversion segment
DENSITY
+
"My practice is my livelihood. Every device I add has to deliver results, comfort, and a real partnership."
Practice
NP-owned medspa or wellness clinic · 1–3 providers · founder is hands-on
Best Channel
Instagram · sales rep · trade shows · email nurture
Lead With
Practical, patient-first, business-of-aesthetics framing — like a smart friend who knows the practice
Top Pillars
Provider's Edge → Human Comfort → Real Results
Wants
Devices that don't sit unused · Day 1 marketing kit · training that respects her time · a rep who picks up the phone
Fights
Devices oversold and abandoned · long ROI cycles · generic co-marketing that doesn't drive bookings
Top Content
Provider features · real practice stories · before/after with clinical context
Post-Purchase
Marketing kit + rep community access · monthly check-in cadence
Jeisys fit

DENSITY entry device. Easy to integrate, NP-administered. The biggest gap to fill is post-purchase support — this is exactly where "Business BFF" (Jeisys' documented voice character — the rep who knows your practice) makes its money.

02
The Practice Lead
Multi-provider medspa · mid-funnel gatekeeper · committee decision
DENSITY Edge ONE
+
"My job is making sure each device pulls its weight and the team can run them all."
Practice
Multi-provider medspa or aesthetic group · 4+ providers · device portfolio across categories
Best Channel
LinkedIn · trade shows · sales rep + MD · email nurture
Lead With
Multi-unit thinking — portfolio fit, peer-chain proof, train-the-trainer economics
Top Pillars
Provider's Edge → Built for Business Growth → Confident Science
Wants
Devices that complement existing portfolio · easy training ramp · clinical claims to sell upward · predictable per-treatment economics
Fights
"Just another device" that cannibalizes existing producers · training-heavy onboarding · reps who don't understand the existing mix
Top Content
Practice case studies · portfolio economics · train-the-trainer proof
Post-Purchase
Benchmarking reports + peer-practice comparisons · advanced training pathway
Jeisys fit

Portfolio addition for collagen / no-downtime gap. Edge ONE's 10-min EdgePolish™ fits high-throughput practice economics perfectly.

03
The Aesthetics-Native Dermatologist
Derm + aesthetics arm · evidence-first · KOL-influenced · peer-validated
Potenza
+
"I read the studies before I take the demo. Show me the data, then show me the device."
Practice
Derm practice with dedicated aesthetics arm · solo or small group MD-led · device-savvy · peer-influenced
Best Channel
LinkedIn clinical thought leadership · AAD/ASDS conferences · clinical email · direct KOL relationships
Lead With
Peer-reviewed evidence, mechanism specificity, KOL-validated protocols — speak provider-to-provider
Top Pillars
Confident Science (highest) → Provider's Edge → Success Backed by Science
Wants
Peer-reviewed clinical evidence · mechanism specificity · KOL endorsements matching her profile · clean integration
Fights
Marketing fluff · "game-changer" language · influencer-led evidence · reps without clinical fluency
Top Content
Clinical depth · mechanism explainers · peer-to-peer KOL validation
Post-Purchase
KOL community access + ongoing CE · clinical content co-creation
Jeisys fit

Potenza gold-standard RF microneedling, peer-validated. The 4-mode delivery and 91% RealSelf "Worth It" score are the clinical differentiators she evaluates before anything else.

04
The Plastic Surgeon
PS practice · aesthetics adjunct · surgical-primary mindset · patient retention focus
Potenza Edge ONE
+
"Surgery is my main practice. Aesthetics is how I keep patients in the chair between procedures."
Practice
PS practice with aesthetics adjunct · MD-led · dedicated aesthetics staff (often NPs) · ROI-driven
Best Channel
ASPS / surgical conferences · sales rep direct (via aesthetics staff) · LinkedIn · practice marketing kit
Lead With
MD-led authority, clinical depth, surgical-patient retention economics — never reduce her to "nurse-led teams"
Top Pillars
Confident Science (highest) → Provider's Edge → Provider-First Partnership
Wants
Devices that retain pre-surgical patients · strong clinical safety record · staff training that runs without her
Fights
"Nurse-led" positioning that ignores her authority · devices that don't extend surgical-patient LTV
Top Content
Surgical-grade outcomes · patient retention economics · staff-operated protocol proof
Post-Purchase
Patient retention framework + LTV data · staff training that runs without her
Jeisys fit

Potenza for surgical-patient retention. Edge ONE for resurfacing adjunct. Both carry the surgical-grade clinical credibility this persona demands before signing any paperwork.

Patient Persona

She's already in the market — and already frustrated by how it talks to her.

The Glow Getter
"I want to look as good as I feel — and I want it to fit into my actual life."
0% Women
0 Median Age
$145K Median HHI
Millions US Aesthetic Procedures Annually
ChannelsInstagram (creator + provider), TikTok (search + reviews), RealSelf, Google, practice IG
Lead withSelf-care framing, openness to share, wellness-stack vocabulary — let the provider handle clinical depth
Top pillarsReal Results, Real People → Human Comfort → Smart Tech That Performs

4 Sub-Segments

01 · Collagen Banker · Ages 25–35

"Build your collagen now, thank yourself later." Pre-juvenation seekers. Self-care framing, not aging-prevention. → DENSITY

02 · Midlife Refresh · Ages 40–55

"Real results, real lives." Natural-looking, no-downtime. Self-care-as-investment mindset. → DENSITY + Edge ONE

03 · GLP-1 User · Ages 35–55

"Restore what GLP-1 takes back." Rapid facial volume loss. Already in the provider system. Doctor-positive. → DENSITY preventative

04 · Natural Rejuvenator · Ages 35–55

"No needles. No fillers. Just your skin, working with you." Low-tox lifestyle, HRT-aware, "luxury granola." → DENSITY + Edge ONE

Persona → Product Fit

Which device leads for each persona — and why the fit is structural, not incidental.

DENSITY device
DENSITY
RF Collagen Stimulation
Owner-Op NP
Sweet spot entry device — NP-administered, easy to integrate, no downtime story sells itself
Practice Lead
Portfolio addition for the collagen + no-downtime gap
Glow Getter
Pre-juvenation entry treatment — "build collagen now." Comfort-first for the needle-averse
Edge ONE device
Edge ONE
Fractional CO₂
Practice Lead
10-min EdgePolish™ fits high-throughput practice economics perfectly
Aesthetics Derm
True CO₂ in editorial register — beauty-media adjacent, peer-citable
Glow Getter
Photo-ready polish positioning. No downtime for a busy life
Potenza device
Potenza
RF Microneedling
Aesthetics Derm
Gold-standard RF microneedling — peer-validated, 4-mode delivery, clinical depth
Plastic Surgeon
Surgical-adjacent — retains pre/post-op patients in the chair between procedures
Practice Lead
Active-treatment / RF microneedling lane — portfolio completion play

The people are mapped. Now let’s look at what a year of content actually taught us.

Jeisys device portfolio
Q1 2026 Signal Report · data through May 4, 2026

Q1 showed us what’s working. Here’s what comes next.

The partner ecosystem has taken over the feed. Practice content is outperforming every other bucket. The audience is talking unprompted. And we’re tracking a data blind spot that comes with doing this right.

61%
of Feb feed was collab-originated

For the first time, the majority of feed content is coming from the partner ecosystem — not from us. That’s the strategy working exactly as intended.

50+
Practice stories in March alone

Practice is the strongest bucket every single month across both feed and stories. The install ecosystem is generating volume we don’t have to manufacture.

12%
Patient feed — vs. 20% target

Patient content is the one consistent gap. Nearly all of it originates from collabs — meaning the content we can’t measure is also the content we need most.

!
Blind Spot
Collab engagement not in Sprout

50%+ of the feed doesn’t flow through Sprout. Any engagement rate we quote reflects owned posts only. We’re tracking volume manually — engagement is still a black box.

The Evidence

Year One told us what works. The data confirmed the strategy — and showed exactly where we left performance on the table.

The Audience Is Already Talking

Real comments. Zero prompting. Pulled from @jeisys_us, May 2025–May 2026.

@user
Instagram comment

Wait is that the Density?? I’ve heard the results are insane

Unprompted · Patient · 2025
@user
Instagram comment

I swear Potenza changed my life! I suffered from cystic acne for years… this device is a miracle.

Unprompted · Patient · 2025
@provider
Instagram comment · Provider

Painless skin tightening is the holy grail! we cant wait to offer this to our clients

Unprompted · Practice account · 2026
@user
Instagram comment

Just finished my 3rd session and the tightening around my jawline is insane

Density patient journey · 2025
@user
Instagram comment

Just had my first Density treatment last week! Zero downtime and no pain is a real thing

Patient · First treatment · 2026
Direct Messages
@jeisys_us inbox · multiple senders

Patients in Houston, LA, NYC, the Pacific Northwest, Greenwich CT, PA, and San Diego are DMing to ask where they can find a provider. The network isn’t there yet.

Inbound demand · May 2025–May 2026
Content Performance · Q1 2026

Two platforms. Two completely different stories.

Instagram is a volume and partner story. LinkedIn is a depth and credibility story. They require different metrics, different content, and different expectations.

February
Collab posts 22
61% of 36 feed posts
Owned posts 14
39% · tracked in Sprout
March
Collab posts 18
51% of 35 feed posts
Owned posts 17
49% · tracked in Sprout
April
Collab posts 23
62% of 37 feed posts
Owned posts 14
38% · tracked in Sprout
⚠

Collab engagement is a blind spot — by design.

Collab posts don’t flow through Sprout. Engagement data for 50%+ of the feed isn’t attributable to @jeisys_us via Meta Business Suite. We’re tracking volume manually. Any engagement rate we quote reflects owned posts only.

Practice is performing to goal

Practice is the strongest bucket every month across both feed and stories. The install ecosystem — provider spotlights, collab posts, rep amplification — is generating steady volume without us manufacturing it.

Brand feed depends on campaigns

March was the only month Brand hit its 30% target — because INNM was running. February and April both came in below. Without an active campaign, Brand goes quiet.

Patient content is the structural gap

Patient feed hasn’t exceeded 12% in any month against a 20% target. Nearly all of it originates from collabs — the content we can’t measure is also the content we need most.

Near & Dear Social Ratio Report · Feb–Apr 2026 · @jeisys_us Instagram · Collab log tracked manually. April collab count in progress.

Three Year-One Lessons

The data confirmed what to double down on.

Finding 01

Practice content outperforms brand content — every time.

UGC and practice-tagged content averaged 3.10% ER vs. 2.87% for branded posts — and the INNM campaign, built on provider imagery and real-world context, hit 4.65%. The account’s top Instagram post (11.84% ER) was a provider welcome reel. When the content feels like it comes from inside the practice, it lands harder. That’s not a hypothesis anymore.

Year Two Move Scale from organic to structured. 45/40/15 content architecture. 8–10 provider partners. Engagement target >7%.
2×
harder than
branded posts
Finding 02

Our moats are underleveraged.

INNM campaign content hit 4.65% ER — the account's best-performing content pillar. Brand and education content averaged 2.87% and 2.34% respectively despite running at higher volume. LinkedIn document posts averaged 34.5% engagement rate across 42 posts, with 91% of all engagements being active clicks into the content. High-volume posting isn't the answer. Right content, right platform, right audience is.

Year Two Move Shift Confident Science to LinkedIn. Reallocate Instagram volume into Comfort and Real Results — the territory no competitor owns.
10%
of volume,
top performance
Finding 03

Edge ONE launched without a support kit.

DENSITY practices have a full infrastructure: consultation guide, front desk script, patient Q&A. Edge ONE practices bought in February with none of it. The content is starting to move. The partnership layer is the next unlock.

Year Two Move Edge ONE support kit on parity with DENSITY. KOL toolkit. Practitioner community build-out.
0
support assets
at launch

Measurement Framework · Retire Vanity Metrics

Stop optimizing for likes. These four signals connect content investment to business outcomes.

0.63
saves / post
Engagement Quality
Saves + shares, not likes. Saves signal intent to return — the metric closest to conversion for a B2B brand.
Track: Per-post save rate · Benchmark: 2× category average
+3,103
IG followers · Year One
Audience Growth (Owned)
Net follower + email list growth. Builds a base to convert against and reduces platform dependence.
Track: Monthly net new · avg +258/mo · Peak Apr +426
7.85%
provider-tagged vs. 4.08% branded
Provider-Creator Rate
Engagement on provider posts vs. owned. Nearly 2× — the quantified case for a structured creator program.
Track: Account classification · per-post engagement log
Q3
2026 · start date
Pipeline Attribution
Content touchpoints in the conversion window. Connects content to revenue — one rep intake question away.
Add: “How did you hear about Jeisys?” to rep intake · review quarterly

The data confirmed the instinct. Now here’s how each buyer actually moves — and where your rep needs to be ready.

Buyer Journeys · Five Personas · Six Stages

Every buyer moves differently.
Here’s the play at each stage.

Each persona follows a distinct journey — different emotional triggers, different friction points, different content that converts. This maps the strategic logic at every stage: what they’re feeling, what moves them, and exactly where the content and collateral gaps are today.

01Select a persona
→
02Select their stage
→
03Here's how you win
Owner-Op NP
Owner-Op NP
Provider
Practice Lead
Practice Lead
Provider
Aesthetics Derm
Aesthetics Derm
Provider
Plastic Surgeon
Plastic Surgeon
Provider
The Glow Getter
The Glow Getter
Patient
←

Select a persona on the left

Each one shows the emotional arc, the strategic play, and what content is missing at every stage of the journey.

The market is ready.
The lane is open.

Here’s how we take it.

The Move

Three plays. Sequenced for the next two quarters. Built on what year one actually proved.

Phase 1 establishes the strategic foundation — diagnosis, positioning, and priority plays. The full execution plan, channel-level content architecture, and campaign briefs are delivered in Phase 2.

The Move

The audience is already rewarding the content we're under-producing. No competitor has claimed the Comfort + Science + Warmth lane. The products are built for it. Three plays operationalize that opening — sequenced, owned, and measurable.

01

Rebalance the Pillar Mix by Channel

Pull volume out of Confident Science on Instagram (where it’s 34% of volume but only 22% of engagement-share) and push into Real Results and Comfort (each pulling their weight on 10% of volume). Channel-aware targets, not flat targets. LinkedIn keeps Confident Science alongside Category Authority — both lead engagement on the channel (39% and 32% of LinkedIn engagement-share, respectively).

Owner Content + Social Measure Engagement rate by pillar · monthly
02

Build the Structured Provider-Creator Program

Move from informal practitioner UGC to a formal 45/40/15 architecture: 45% provider-creator content, 40% owned @jeisys_us, 15% sales team. Recruit 8–10 provider partners with light briefs and cross-tag rules. Target engagement rate above 7% (vs. 4.08% for branded sales content).

Owner Brand + KOL Measure Provider-creator rate >7% · 8–10 enrolled
03

Add the Post-Purchase Business BFF Layer

Build the partnership infrastructure the homepage promises. Edge ONE practice support kit on parity with DENSITY. KOL toolkit for all three devices. /providers section with Section 179 as a gated download. This is what makes the “Business BFF” positioning real instead of just brand language.

Owner Brand + Sales Enablement Measure Edge ONE parity score · Provider-creator enrollment
The Retention Architecture

Retention isn’t a follow-up program.
It’s where “Business BFF” stops being a tagline.

The single most consistent complaint in HCP research: “Abandoned after the sale.” Most device brands disappear the moment the check clears. That’s not a service gap — it’s a strategic opening. Three moments define whether Jeisys earns the word partner or becomes another cautionary tale.

Key:
Solo Provider Chain Buyer Switcher Patient-Facing
01
Win the First 90 Days — Consumables

Every practice finds out within 90 days whether consumables ordering is frictionless or a support ticket. Most device brands fail this test quietly — and it’s where post-sale skepticism starts. Jeisys wins the partnership-perception battle here, before a competitor even gets a foot in the door. This is also a significant and growing revenue stream — one that compounds with every new install.

Solo — Proactive reorder cadence before they run out · loyalty pricing that rewards early adopters Chain — Multi-unit standing orders with account-level visibility · no location left waiting Conquest — Service-continuity confidence for practices leaving a brand with supply uncertainty
02
Turn Customers Into the Program — Enrollment

A satisfied provider is a dormant asset. A enrolled provider is an active one. Structured programs convert post-purchase goodwill into measurable advocacy — content, referrals, and social proof that no paid media budget can replicate. This is the mechanism that turns the install base into Jeisys’s most credible sales channel.

Solo — INNM Magician KOL pathway · structured advocacy enrollment Chain — Multi-unit case study program · QBR with real utilization data Conquest — Migration testimonial program · switcher story as the most persuasive peer content available Patient — Glow Getter loyalty, provider-led · UGC kits + referral content every quarter
03
Build the Community No Competitor Has — Relationships

Competitors train providers. Jeisys builds a network. The difference between a practice that stays and a practice that switches is almost never the device — it’s whether they feel like they belong to something. NSM invitations, peer-to-peer community, and a rep who knows their practice by name: that’s the moat no incumbent has bothered to build.

Solo — INNM Magician community · NSM invitations · rep relationship that outlasts the sale Chain — Account-level QBRs · cross-location peer connections · Jeisys as a strategic growth partner Conquest — Switcher peer-to-peer community · the most persuasive voice for the next undecided practice Patient — Provider IG amplification · Glow Getter referral loop back into the practice
The compounding effect

Each window builds on the last. Win consumables and you earn the right to enroll them. Enroll them and you earn the right to build community. Build community and the install base becomes the sales team — and the partnership promise becomes self-reinforcing.

Messaging Platform · How Claims Are Governed

Every claim. Two versions. One source.

The Messaging Platform v2.3 governs every approved claim across DENSITY, Potenza, and Edge ONE. Each claim is built twice — once for the provider conversation, once for the patient. Each clinical stat cites its source. Each trademark has a usage rule. This is how Near & Dear ensures brand consistency at scale.

The Claim B2B Version B2C Version
DENSITY collagen output Delivers up to 5× more collagen than monopolar RF alone — meaning more structural improvement, better skin quality, and results patients can see and feel.* Up to 5× more collagen than older RF treatments* — firmer, smoother, healthier-looking skin.
Potenza patient satisfaction 91% RealSelf "Worth It" score — one of the highest ratings in the RF microneedling category. Use in sales conversations as third-party social proof. 91% of patients say it's worth it. That's not a claim — that's a crowd.
EdgePolish™ positioning The anytime 10-minute skin polish — fast to perform, easy to protocol, and a natural upsell from peels and HydraFacials. A 10-minute polish that leaves skin glowing. No downtime, no prep — just photo-ready skin.

*Collagen data: International Journal of Molecular Sciences, PMC8950306. All claims sourced per Messaging Platform v2.3 · February 2026.
*RealSelf Worth It scores sourced from RealSelf.com, April 2026 snapshot. Scores update in real time — verify before external use.

Phase 1 Source Documents

The full research library.

Every finding in this document traces back to one of these deliverables. Final versions will be available for download at handoff.

Gaps & Pain Points
Near & Dear · Apr 2026
Pending final
Provider & Patient Personas
Near & Dear · Apr 2026
Pending final
Customer Journey Maps
Near & Dear · Apr 2026
Pending final
Year One Content Audit
Near & Dear · Apr 2026
Pending final
Competitive Audit
Near & Dear · Apr 2026
Pending final
Messaging Platform v2.3
Near & Dear · Apr 2026
Pending final
Voice & Tone v1.2
Near & Dear · Apr 2026
Pending final
What’s Next · Phase 2 + Phase 3

From strategy to systems.

Phase 1 made the case. The next two quarters operationalize it — three workstreams that build the content engine, the channel architecture, and the measurement layer. Every deliverable maps to the 2026 Content + Social Media Tactical Plan.

01

The Content Engine

Central editorial calendar across Social, Email, Web, and Sales. Pillars and narrative themes mapped to channel-aware cadence. Evergreen + SEO/GEO content. INNM Year Two creative pipeline. Monthly content kits for sales and practitioners.

02

The Channel Map

Eight-surface channel architecture — Instagram, LinkedIn, Email, Web, Sales Collateral, Practitioner Toolkits, Paid Media, YouTube. Owned / Earned / Paid strategy matrix. Brand creative refresh across platforms. Field-activation playbook for sales and practitioners.

03

The Measurement Layer

KPI framework and per-channel benchmarks. Optimization guidance baked into the workflow. Community management approach. Monthly pacing reports plus quarterly strategic check-ins — the data that keeps the strategy living, not frozen.

Terminology A quick reference for the terms used throughout
HCP
Healthcare provider — physicians, NPs, PAs, RNs delivering treatments.
NP
Nurse practitioner — often the operator and frequent owner-operator in solo aesthetic practices.
KOL
Key opinion leader — a respected provider whose endorsement moves peers and patients.
OOH
Out-of-home — billboards, transit, in-clinic placements; offline brand presence.
UGC
User-generated content — patient-shot or provider-shot social posts that aren’t branded production.
QBR
Quarterly business review — recurring strategic check-in chain buyers expect from device partners.
Section 179
U.S. tax provision letting practices deduct full equipment cost in year of purchase — central to the conversion math.
RealSelf
Patient-review platform; the “Worth It” score is a leading indicator of category sentiment.
RFMN
Radiofrequency microneedling — the device category Potenza, Morpheus8, and Secret RF compete in.
PIH
Post-inflammatory hyperpigmentation — a documented risk in Fitzpatrick IV+ skin with many devices.
HHI
Household income — demographic anchor for the Glow Getter patient persona ($145K median).
FDA
U.S. Food & Drug Administration — clearance status and indications for use.
EdgePolish™
The 10-minute, zero-downtime CO₂ resurfacing protocol — the entry-tier of Edge ONE’s three-tier ladder (Polish, Rejuvenation, Deep Renewal).
INNM
“It’s Not Not Magic” — Jeisys’ active campaign positioning the devices as so effective they feel magical.
Magician
Brand archetype for providers who deliver magical-feeling results — the persona around which Provider’s Edge content is built.
MRI Aesthetics
Independent research firm; Phase 1 patient study source (n=73% women, median age 37).
Okay Human
HCP research firm; n=30 provider qualitative interviews informing the pain-point work.
Comfort + Science + Warmth
The unclaimed competitive lane Jeisys is positioned to own — the strategic frame underwriting every play.

Near & Dear · Prepared for Jeisys Medical North America · April 2026 · Confidential

Data current as of May 5, 2026 · Pacing report May 4, 2026 · Audit workbook + competitive audit April 2026 · RealSelf scores update in real time, verify before external use